Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic

Further demonstrates confidence in Marengo's novel T cell biology-focused approach to target TCR Vβ for the activation of anti-tumor immune response with its bi-specific STAR platform CAMBRIDGE, Mass., May 9, 2022 -- (Healthcare Sales & Marketing N... Biopharmaceuticals, Oncology, Personnel Marengo Therapeutics, Selective T Cell Activation Repertoire
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news